溶性关酸环酶刺激剂对心血管的影响:随机对照试验的元分析
Cosimo Andrea Stamerra1, Paolo Di Giosia1, Paolo Giorgini2
1Department of Internal Medicine-Mazzoni Hospital, Ascoli Piceno, Italy.
Current atherosclerosis reports
|April 2, 2024
概括
溶性酸环酶 (sGCs) 刺激剂显著改善了心脏功能标志物,如NT-pro-BNP和心力衰竭患者的射出分数. 然而,在此元分析中,sGCs并没有对全因死亡率产生显著影响.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 心力衰竭 (HF) 是全球心血管死亡的主要原因.
- 尽管取得了进展,但HF复发率和死亡率仍然很高.
- 溶性瓜尼酸环酶 (sGC) 通过cGMP生产在血管扩张和心肌性能方面发挥着至关重要的作用.
研究的目的:
- 评估心力衰竭患者中sGC刺激器 (sGCs) 的治疗效果.
- 分析sGCs对心血管结果的影响,包括NT-pro-BNP水平,射出分数 (EF) 和全因死亡率.
主要方法:
- 在Medline,SCOPUS和谷歌学者中进行了系统的文献搜索,直到2022年12月.
- 包括随机对照试验 (RCT),评估sGCs治疗的HF患者的心血管影响和死亡率.
- 量化数据综合采用了具有加权平均差异 (WMD) 和95%置信区间 (CI) 的随机效应模型.
主要成果:
- sGCs的使用导致NT-pro-BNP值在统计学上显著改善 (SMD: -0.258;95%CI: -0.398, -0.118).
- 观察到射出分数 (EF) 的显著改善 (WMD: 0.948; 95% CI: 0.485, 1.411).
- 没有发现任何原因死亡率的显著变化 (RR:0.96;95% CI:0.868至1.072).
结论:
- sGC刺激剂代表了管理心力衰竭的可行治疗策略.
- sGCs有效地改善了HF患者的心脏表现标记.
- 可能需要进一步的研究来确定sGCs对心力衰竭死亡率的长期影响.
相关概念视频
Antianginal Drugs: Nitrates and β-Blockers
580
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
580
GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K
Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516
Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K


